At the news
? BULLISHIMPACT 6/10 8-K filed Nov 4, 2026 at 16:21 ET
Edwards Lifesciences reported Q3 2026 adjusted EPS of $0.80, beating the $0.74 consensus by 8.1%, on revenue of $1.72B, above the $1.68B consensus. The company raised full-year 2026 sales growth guidance to approximately 11.5% (from 10-11%), TAVR growth to 9.0-9.5%, and adjusted EPS guidance to $2.97-$3.05. TMTT sales grew 44% YoY to $207M, and the PROGRESS trial data and final TAVR NCD were highlighted as key catalysts.
- Q3 2026 sales grew 10.5% to $1.72B, constant currency growth 11.2%
- Q3 adjusted EPS $0.80, up 19% YoY, beating consensus of $0.74
- TAVR sales grew 8.0% to $1.24B, constant currency growth 8.8%
- TMTT sales grew 44.0% to $207M, constant currency growth 45.6%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access